Effects of Active Versus Passive Recharge Burst Spinal Cord Stimulation on Pain Experience in Persistent Spinal Pain Syndrome Type 2: A Multicenter Randomized Trial (BURST-RAP Study)

Sponsor
Rijnstate Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05421273
Collaborator
Abbott (Industry), Medtronic (Industry)
96
6
2
22.4
16
0.7

Study Details

Study Description

Brief Summary

Spinal cord stimulation (SCS) has shown to be an effective treatment for patients with persistent spinal pain syndrome Type 2 (PSPS Type 2). The method used to deliver electrical charge in SCS is important. One such method is burst stimulation. Two variations of burst waveforms are currently in use: one that employs active recharge and one that uses passive recharge. It is still unknown if there are clinical differences between active recharge and passive recharge burst SCS. To date, no clinical studies have been performed that directly compared these two burst stimulation waveforms. The objective of this Randomized Clinical Trial (RCT) is to assess and compare effect of passive recharge burst SCS with active recharge burst SCS on pain relief and motivational-emotional facets of pain

Condition or Disease Intervention/Treatment Phase
  • Device: Spinal cord stimulation using passive recharge burst stimulation
  • Device: Spinal cord stimulation using active recharge burst stimulation
N/A

Detailed Description

This multicenter randomized clinical trial will take place in 6 Dutch hospitals: the Rijnstate Hospital (Arnhem), Bravis Hospital (Roosendaal), Elizabeth TweeSteden Hospital (Tilburg), Diakonessen Hospital (Utrecht), Alrijne Hospital (Leiden) and the Amsterdam University Medical Hospitals A-UMC). PSPS Type II2 patients (n=96) will be randomized into a group receiving either active or passive recharge burst. Following a successful trial period, patients are permanently implanted. Patients complete the pain catastrophizing score (PCS) (primary outcome at 6 months), numeric pain rating scale (NRS), patient vigilance and awareness questionnaire (PVAQ), hospital anxiety and depression scale (HADS), quality of life (EQ-5D), Oswestery disability index (ODI), patient global impression of change (PGIC) and painDETECT questionnaires (secondary outcomes) at baseline, after trial, 1, 3, 6 and 12 months following implantation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Active Versus Passive Recharge Burst Spinal Cord Stimulation on Pain Experience in Persistent Spinal Pain Syndrome Type 2: A Multicenter Randomized Trial (BURST-RAP Study)
Actual Study Start Date :
Feb 16, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active recharge burst stimulation

Device: Spinal cord stimulation using active recharge burst stimulation
Active recharge burst is characterized by negative pulses that directly compensate for charge differences.

Experimental: Passive recharge burst stimulation

Device: Spinal cord stimulation using passive recharge burst stimulation
Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.

Outcome Measures

Primary Outcome Measures

  1. Pain catastrophizing score [6 months]

Secondary Outcome Measures

  1. Numeric pain rating scale [3, 6, 12 months]

  2. Patient vigilance and awareness questionnaire [3, 6, 12 months]

  3. Hospital anxiety and depression scale [3, 6, 12 months]

  4. EQ-5D questionnaire [3, 6, 12 months]

    Quality of life questionnaire

  5. Oswestery disability index [3, 6, 12 months]

  6. Patient global impression of change [3, 6, 12 months]

  7. PainDETECT questionnaire [3, 6, 12 months]

    Characterisation of neuropathic pain components

  8. Mean charge per second used [3, 6, 12 months]

    Measures the amount of electrical charge used

  9. Mean charge per hour used [3, 6, 12 months]

    Measures the amount of electrical charge used

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects between 18 and 70 years of age

  • At least moderate level of catastrophizing as measured with the Pain catastrophizing scale (PCS) of at least 20 at first visit of the pain clinic.

  • Chronic pain diagnoses as PSPS Type 2 of at least 6 months

  • Neurologic exam without marked motor deficit.

  • LBP and/or leg pain intensity should be 5 or higher measured with the 11-box NRS 0-10

  • Meets all the inclusion criteria for the implantation of a neurostimulation system as typically utilized in the study center. PM: depression is not an exclusion criteria

  • Subject has been screened by a multi-disciplinary panel including a psychologist and deemed suitable for implantation

  • Subject is able and willing to comply with the follow-up schedule and protocol

  • Subject is able to provide written informed consent

Exclusion Criteria:
  • Female subject of childbearing potential is pregnant/nursing or plans to become pregnant during the course of the study

  • Escalating or changing pain condition within the past month as evidenced by investigator examination

  • BMI ≥35

  • "Subject has had injection therapy or radiofrequency treatment for their low back pain (LBP) or leg pain within the past 3 months"

  • Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump

  • Subject is unable to operate the device

  • Severe spinal column degeneration likely to cause technical problems with neuromodulation, to be assessed by the treating physician

  • Previous Neurostimulation therapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rijnstate Hospital Arnhem Gelderland Netherlands 6815 AD
2 Bravis Hospital Roosendaal Noord-Brabant Netherlands 4708 AE
3 Elizabeth TweeSteden Hospital Tilburg Noord-Brabant Netherlands 5042 AD
4 Amsterdam University Medical Hospitals A-UMC Amsterdam Noord-Holland Netherlands 1105 AZ
5 Diakonessen Hospital Zeist Utrecht Netherlands 3707 HL
6 Alrijne Hospital Leiderdorp Zuid-Holland Netherlands 2353 GA

Sponsors and Collaborators

  • Rijnstate Hospital
  • Abbott
  • Medtronic

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT05421273
Other Study ID Numbers:
  • NL75451.091.020
First Posted:
Jun 16, 2022
Last Update Posted:
Jun 16, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2022